Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib, Cadonilimab, and Temozolomide in Advanced Melanoma
NCT06553781Not yet recruiting
- Sponsor
- Fudan University
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Fragment-Derived Small Molecules, Bispecific Antibodies, Allosteric Modulators
01
Overview
Open-label, single-arm trial of fruquintinib and cadonilimab in Malignant Melanoma (MM), sponsored by Fudan University. Primary endpoint: Objective Response Rate at 5 months. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
fruquintinibcadonilimab
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT06553781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06553781.